title: rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity.
abstract: Chemotherapy (CT) in advanced and metastatic soft tissue sarcoma (STS) has a reported response rate of 17 to 30%, with a median survival of 30 months. Experimental and clinical studies have demonstrated some response with high-dose intravenous recombinant Interleukin-2 (r-IL2). We report a retrospective analysis of twelve patients with metastatic or locally evolutive STS who received high-dose rIL-2 immunotherapy: all patients were pre-treated with CT and were non responsive. All of these patients developed usual severe toxicity. One patient achieved a partial response with rIL-2 with more than 75% regression of lung metastases. All patients received CT post rIL-2 and 2 of them achieved a further response: 1 of them had a complete response (CR), and one had a partial response (PR). These results suggest that rIL-2 has a relatively low efficacy in patients with STS but that some of these patients can be, after rIL-2, responders to CT despite previous resistance.
authors.affiliation: Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Gravis
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: R
authors.initials: R
authors.lastname: Delva
authors.forename: D
authors.initials: D
authors.lastname: Baume
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: F
authors.initials: F
authors.lastname: Ternier
authors.forename: G
authors.initials: G
authors.lastname: Houvenaeghel
authors.forename: M
authors.initials: M
authors.lastname: Brandely
authors.forename: M
authors.initials: M
authors.lastname: Resbeut
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology; D012509:Sarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins